A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients

(2021) Touria Mernissi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors

(2021) Milo Gatti et al.   Expert Review of Clinical Pharmacology

Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies

(2021) Benoit Llopis et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients

(2020) Marco Falcone et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively- and pan-resistant Acinetobacter baumannii

(2020) A. Oliva et al.   Journal of Global Antimicrobial Resistance

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects

(2019) Takayuki Katsube et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review

(2019) Chandra Datta Sumi et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin

(2019) Takayuki Katsube et al.   CLINICAL INFECTIOUS DISEASES

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

(2018) Krystyna M. Kazmierczak et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Managing Acinetobacter baumannii infections

(2018) José Garnacho-Montero et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria

(2017) Vincent H. Tam et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CharacterizingIn VivoPharmacodynamics of Carbapenems against Acinetobacter baumannii in a Murine Thigh Infection Model To Support Breakpoint Determinations

(2013) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model

(2010) P. J. Bergen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models

(2010) R. V. Dudhani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY